Acarix AB (publ)
Acarix AB (publ), a medical device company, develops solutions for rapid AI-based coronary artery disease rule-out. The company offers CADScor System, a point-of-care diagnostic aid that uses sensitive acoustics and advanced computational processing to analyze the patient's coronary blood flow. It sells its products in the Nordic countries, the United Kingdom, Germany, Switzerland, Austria, Mauri… Read more
Acarix AB (publ) (ACIXF) - Net Assets
Latest net assets as of September 2025: $38.48 Million USD
Based on the latest financial reports, Acarix AB (publ) (ACIXF) has net assets worth $38.48 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($42.10 Million) and total liabilities ($3.62 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $38.48 Million |
| % of Total Assets | 91.4% |
| Annual Growth Rate | 44.3% |
| 5-Year Change | -7.84% |
| 10-Year Change | 5164.06% |
| Growth Volatility | 367.04 |
Acarix AB (publ) - Net Assets Trend (2014–2024)
This chart illustrates how Acarix AB (publ)'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Acarix AB (publ) (2014–2024)
The table below shows the annual net assets of Acarix AB (publ) from 2014 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $75.70 Million | +45.89% |
| 2023-12-31 | $51.88 Million | +0.12% |
| 2022-12-31 | $51.83 Million | -48.46% |
| 2021-12-31 | $100.54 Million | +22.41% |
| 2020-12-31 | $82.14 Million | +7.22% |
| 2019-12-31 | $76.60 Million | +672.61% |
| 2018-12-31 | $9.91 Million | -36.92% |
| 2017-12-31 | $15.72 Million | -7.94% |
| 2016-12-31 | $17.07 Million | +1087.37% |
| 2015-12-31 | $1.44 Million | -25.60% |
| 2014-12-31 | $1.93 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Acarix AB (publ)'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 60813505100.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | $691.72 Million | 913.80% |
| Total Equity | $75.70 Million | 100.00% |
Acarix AB (publ) Competitors by Market Cap
The table below lists competitors of Acarix AB (publ) ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
TWi Biotechnology, Inc.
TWO:6610
|
$26.42 Million |
|
Pacific Century Premium Developments Limited
PINK:PCPDF
|
$26.42 Million |
|
ENGIE Eps S.A
F:8XE
|
$26.43 Million |
|
ELUON Corporation
KQ:065440
|
$26.43 Million |
|
Mohenz.Co.Ltd
KQ:006920
|
$26.41 Million |
|
Benfica
LS:SLBEN
|
$26.41 Million |
|
Wheels Up Experience Inc
NYSE:UP
|
$26.39 Million |
|
FSA Group Ltd
AU:FSA
|
$26.38 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Acarix AB (publ)'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 51,885,000 to 75,697,000, a change of 23,812,000 (45.9%).
- Net loss of 66,187,000 reduced equity.
- New share issuances of 86,980,000 increased equity.
- Other comprehensive income decreased equity by 4,110,000.
- Other factors increased equity by 7,129,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-66.19 Million | -87.44% |
| Share Issuances | $86.98 Million | +114.91% |
| Other Comprehensive Income | $-4.11 Million | -5.43% |
| Other Changes | $7.13 Million | +9.42% |
| Total Change | $- | 45.89% |
Book Value vs Market Value Analysis
This analysis compares Acarix AB (publ)'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.33x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has increased from 0.17x to 0.33x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2014-12-31 | $0.14 | $0.02 | x |
| 2015-12-31 | $0.13 | $0.02 | x |
| 2016-12-31 | $1.30 | $0.02 | x |
| 2017-12-31 | $0.68 | $0.02 | x |
| 2018-12-31 | $0.43 | $0.02 | x |
| 2019-12-31 | $3.01 | $0.02 | x |
| 2020-12-31 | $0.83 | $0.02 | x |
| 2021-12-31 | $0.60 | $0.02 | x |
| 2022-12-31 | $0.20 | $0.02 | x |
| 2023-12-31 | $0.11 | $0.02 | x |
| 2024-12-31 | $0.07 | $0.02 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Acarix AB (publ) utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -87.44%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -1067.19%
- • Asset Turnover: 0.08x
- • Equity Multiplier: 1.07x
- Recent ROE (-87.44%) is below the historical average (-79.99%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2014 | -127.02% | 0.00% | 0.00x | 1.21x | $-2.65 Million |
| 2015 | -102.09% | 0.00% | 0.00x | 1.28x | $-1.61 Million |
| 2016 | -31.02% | 0.00% | 0.00x | 1.11x | $-7.00 Million |
| 2017 | -23.09% | -4667.13% | 0.00x | 1.04x | $-5.20 Million |
| 2018 | -48.08% | -4126.00% | 0.01x | 1.08x | $-5.76 Million |
| 2019 | -60.65% | -2501.83% | 0.02x | 1.08x | $-54.12 Million |
| 2020 | -50.52% | -1912.26% | 0.02x | 1.10x | $-49.71 Million |
| 2021 | -51.45% | -1375.82% | 0.03x | 1.18x | $-61.79 Million |
| 2022 | -148.55% | -1322.31% | 0.08x | 1.34x | $-82.17 Million |
| 2023 | -150.02% | -1247.22% | 0.10x | 1.21x | $-83.03 Million |
| 2024 | -87.44% | -1067.19% | 0.08x | 1.07x | $-73.76 Million |
Industry Comparison
This section compares Acarix AB (publ)'s net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $771,729,193
- Average return on equity (ROE) among peers: -14.17%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Acarix AB (publ) (ACIXF) | $38.48 Million | -127.02% | 0.09x | $26.42 Million |
| Advanced Biomedical Technologies Inc (ABMT) | $-4.46 Million | 0.00% | 0.00x | $14.18K |
| Abbott Laboratories (ABT) | $4.82 Billion | 39.04% | 1.31x | $191.37 Billion |
| Adagio Medical Holdings, Inc Common Stock (ADGM) | $-72.62 Million | 0.00% | 0.00x | $4.05 Million |
| Adm Tronics Unltd (ADMT) | $-12.69K | 0.00% | 0.00x | $3.17 Million |
| Aethlon Medical Inc (AEMD) | $-3.07 Million | 0.00% | 0.00x | $2.79 Million |
| Acutus Medical Inc (AFIB) | $126.58 Million | -80.56% | 0.52x | $732.88K |
| Adapthealth Corp (AHCO) | $2.07 Billion | 7.56% | 1.54x | $914.25 Million |
| Allied Healthcare Products Inc. (AHPIQ) | $8.88 Million | -33.95% | 1.22x | $726.24 |
| 20/20 Biolabs, Inc. Common Stock (AIDX) | $3.39 Million | -59.65% | 0.38x | $9.18 Million |